Human Papillomavirus Vaccine Market By Type (Tetravalent, Nonavalent, Bivalent), By Disease Indication (Cervical Cancer, Anal Cancer, Vulvar & Vaginal Cancer, Penile Cancer, Oropharyngeal Cancer, Others), By Industry Vertical (Public and Private Alliances, Government Entities, Physicians, Others): Global Opportunity Analysis and Industry Forecast, 2021-2030
The global human papillomavirus vaccine market size was valued at $3,892.7 million in 2021 and is projected to reach $10,823.0 million by 2030, growing at a CAGR of 12.4% from 2022 to 2030.
As the prevalence of human papillomavirus diseases grows, so does the market for human papillomavirus vaccines. The development of new HPV vaccines, as well as increased initiatives by government and commercial organizations for early screening and vaccination, are propelling the human papillomavirus (HPV) vaccine market forward. The rising incidence of HPV-related malignancies in the anal, oropharynx, and genital regions, as well as increased demand for HPV vaccinations to help decrease infections, are expected to keep the market growing steadily in the coming years.
Healthcare expenditures, on the other hand, are skyrocketing, with the drive toward prevention. Vaccination costs have risen from the single digits to triple digits several times over the last two decades, posing considerable issues for doctors and their patients while also putting a strain on public health funding.
The global human papillomavirus vaccine market trends is segmented on the basis of type, disease indication, industry vertical and region. Based on type, the market has been divided into tetravalent, nonavalent, and bivalent. Based on disease indication, the market has been divided into cervical cancer, anal cancer, vulvar & vaginal cancer, penile cancer, oropharyngeal cancer, and others. Based on industry vertical, the market has been divided into public and private alliances, government entities, physicians, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players profiled in this report include GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Sanofi S.A., Novartis AG, Serum Institute of India Pvt. Ltd., Bharat Biotech, Inovio Pharmaceuticals, Inc and Xenetic Biosciences, Inc. among others.
Key Market Segments
By Type
Tetravalent
Nonavalent
Bivalent
By Disease Indication
Cervical Cancer
Anal Cancer
Vulvar Vaginal Cancer
Penile Cancer
Oropharyngeal Cancer
Others
By Industry Vertical
Public and Private Alliances
Government Entities
Physicians
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
United Arab Emirates
South Africa
Rest of LAMEA
Key Market Players
Merck & Co., Inc
GlaxoSmithKline plc.
Sanofi
Johnson & Johnson
AstraZeneca
Serum Institute of India Pvt. Ltd
Bharat Biotech.
Xenetic Biosciences, Inc.
Inovio Pharmaceuticals, Inc
Novartis AG
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- 3.7.Value Chain Analysis
- 3.8.Key Regulation Analysis
- 3.9.Patent Landscape
- 3.10.Regulatory Guidelines
- 3.11.Market Share Analysis
- CHAPTER 4: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Tetravalent
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Nonavalent
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Bivalent
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- CHAPTER 5: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Cervical Cancer
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Anal Cancer
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Vulvar & Vaginal Cancer
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.5 Penile Cancer
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
- 5.6 Oropharyngeal Cancer
- 5.6.1 Key market trends, growth factors and opportunities
- 5.6.2 Market size and forecast, by region
- 5.6.3 Market analysis by country
- 5.7 Others
- 5.7.1 Key market trends, growth factors and opportunities
- 5.7.2 Market size and forecast, by region
- 5.7.3 Market analysis by country
- CHAPTER 6: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Public and Private Alliances
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Government Entities
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Physicians
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- 6.5 Others
- 6.5.1 Key market trends, growth factors and opportunities
- 6.5.2 Market size and forecast, by region
- 6.5.3 Market analysis by country
- CHAPTER 7: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Type
- 7.2.3 North America Market size and forecast, by Disease Indication
- 7.2.4 North America Market size and forecast, by Industry Vertical
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Type
- 7.2.5.1.2 Market size and forecast, by Disease Indication
- 7.2.5.1.3 Market size and forecast, by Industry Vertical
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Type
- 7.2.5.2.2 Market size and forecast, by Disease Indication
- 7.2.5.2.3 Market size and forecast, by Industry Vertical
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Type
- 7.2.5.3.2 Market size and forecast, by Disease Indication
- 7.2.5.3.3 Market size and forecast, by Industry Vertical
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Type
- 7.3.3 Europe Market size and forecast, by Disease Indication
- 7.3.4 Europe Market size and forecast, by Industry Vertical
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Type
- 7.3.5.1.2 Market size and forecast, by Disease Indication
- 7.3.5.1.3 Market size and forecast, by Industry Vertical
- 7.3.5.2 United Kingdom
- 7.3.5.2.1 Market size and forecast, by Type
- 7.3.5.2.2 Market size and forecast, by Disease Indication
- 7.3.5.2.3 Market size and forecast, by Industry Vertical
- 7.3.5.3 France
- 7.3.5.3.1 Market size and forecast, by Type
- 7.3.5.3.2 Market size and forecast, by Disease Indication
- 7.3.5.3.3 Market size and forecast, by Industry Vertical
- 7.3.5.4 Spain
- 7.3.5.4.1 Market size and forecast, by Type
- 7.3.5.4.2 Market size and forecast, by Disease Indication
- 7.3.5.4.3 Market size and forecast, by Industry Vertical
- 7.3.5.5 Italy
- 7.3.5.5.1 Market size and forecast, by Type
- 7.3.5.5.2 Market size and forecast, by Disease Indication
- 7.3.5.5.3 Market size and forecast, by Industry Vertical
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Type
- 7.3.5.6.2 Market size and forecast, by Disease Indication
- 7.3.5.6.3 Market size and forecast, by Industry Vertical
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Disease Indication
- 7.4.4 Asia-Pacific Market size and forecast, by Industry Vertical
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 China
- 7.4.5.1.1 Market size and forecast, by Type
- 7.4.5.1.2 Market size and forecast, by Disease Indication
- 7.4.5.1.3 Market size and forecast, by Industry Vertical
- 7.4.5.2 Japan
- 7.4.5.2.1 Market size and forecast, by Type
- 7.4.5.2.2 Market size and forecast, by Disease Indication
- 7.4.5.2.3 Market size and forecast, by Industry Vertical
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Type
- 7.4.5.3.2 Market size and forecast, by Disease Indication
- 7.4.5.3.3 Market size and forecast, by Industry Vertical
- 7.4.5.4 South Korea
- 7.4.5.4.1 Market size and forecast, by Type
- 7.4.5.4.2 Market size and forecast, by Disease Indication
- 7.4.5.4.3 Market size and forecast, by Industry Vertical
- 7.4.5.5 Australia
- 7.4.5.5.1 Market size and forecast, by Type
- 7.4.5.5.2 Market size and forecast, by Disease Indication
- 7.4.5.5.3 Market size and forecast, by Industry Vertical
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Type
- 7.4.5.6.2 Market size and forecast, by Disease Indication
- 7.4.5.6.3 Market size and forecast, by Industry Vertical
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Type
- 7.5.3 LAMEA Market size and forecast, by Disease Indication
- 7.5.4 LAMEA Market size and forecast, by Industry Vertical
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Type
- 7.5.5.1.2 Market size and forecast, by Disease Indication
- 7.5.5.1.3 Market size and forecast, by Industry Vertical
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Type
- 7.5.5.2.2 Market size and forecast, by Disease Indication
- 7.5.5.2.3 Market size and forecast, by Industry Vertical
- 7.5.5.3 United Arab Emirates
- 7.5.5.3.1 Market size and forecast, by Type
- 7.5.5.3.2 Market size and forecast, by Disease Indication
- 7.5.5.3.3 Market size and forecast, by Industry Vertical
- 7.5.5.4 South Africa
- 7.5.5.4.1 Market size and forecast, by Type
- 7.5.5.4.2 Market size and forecast, by Disease Indication
- 7.5.5.4.3 Market size and forecast, by Industry Vertical
- 7.5.5.5 Rest of LAMEA
- 7.5.5.5.1 Market size and forecast, by Type
- 7.5.5.5.2 Market size and forecast, by Disease Indication
- 7.5.5.5.3 Market size and forecast, by Industry Vertical
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Merck & Co., Inc
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 GlaxoSmithKline plc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Sanofi
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Johnson & Johnson
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 AstraZeneca
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Serum Institute of India Pvt. Ltd
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Bharat Biotech.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Xenetic Biosciences, Inc.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Inovio Pharmaceuticals, Inc
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Novartis AG
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 2. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR TETRAVALENT, BY REGION, 2021-2030 ($MILLION)
- TABLE 3. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR TETRAVALENT, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 4. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR NONAVALENT, BY REGION, 2021-2030 ($MILLION)
- TABLE 5. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR NONAVALENT, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 6. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR BIVALENT, BY REGION, 2021-2030 ($MILLION)
- TABLE 7. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR BIVALENT, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 9. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR CERVICAL CANCER, BY REGION, 2021-2030 ($MILLION)
- TABLE 10. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR CERVICAL CANCER, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 11. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR ANAL CANCER, BY REGION, 2021-2030 ($MILLION)
- TABLE 12. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR ANAL CANCER, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 13. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR VULVAR & VAGINAL CANCER, BY REGION, 2021-2030 ($MILLION)
- TABLE 14. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR VULVAR & VAGINAL CANCER, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 15. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR PENILE CANCER, BY REGION, 2021-2030 ($MILLION)
- TABLE 16. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR PENILE CANCER, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 17. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR OROPHARYNGEAL CANCER, BY REGION, 2021-2030 ($MILLION)
- TABLE 18. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR OROPHARYNGEAL CANCER, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 19. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR OTHERS, BY REGION, 2021-2030 ($MILLION)
- TABLE 20. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR OTHERS, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 21. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 22. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR PUBLIC AND PRIVATE ALLIANCES, BY REGION, 2021-2030 ($MILLION)
- TABLE 23. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR PUBLIC AND PRIVATE ALLIANCES, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 24. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR GOVERNMENT ENTITIES, BY REGION, 2021-2030 ($MILLION)
- TABLE 25. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR GOVERNMENT ENTITIES, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 26. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR PHYSICIANS, BY REGION, 2021-2030 ($MILLION)
- TABLE 27. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR PHYSICIANS, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 28. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, FOR OTHERS, BY REGION, 2021-2030 ($MILLION)
- TABLE 29. HUMAN PAPILLOMAVIRUS VACCINE MARKET FOR OTHERS, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 30. HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY REGION, 2021-2030 ($MILLION)
- TABLE 31. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 32. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 33. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 34. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 35. U.S. HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 36. U.S. HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 37. U.S. HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 38. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 39. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 40. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 41. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 42. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 43. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 44. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 45. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 46. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 47. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 48. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 49. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 50. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 51. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 52. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 53. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 54. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 55. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 56. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 57. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 58. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 59. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 60. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 61. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 62. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 63. REST OF EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 64. REST OF EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 65. REST OF EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 66. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 67. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 68. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 69. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 70. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 71. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 72. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 73. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 74. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 75. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 76. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 77. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 78. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 79. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 80. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 81. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 82. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 83. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 84. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 85. REST OF ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 86. REST OF ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 87. REST OF ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 88. LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 89. LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 90. LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 91. LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 92. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 93. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 94. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 95. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 96. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 97. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 98. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 99. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 100. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 101. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 102. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 103. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 104. REST OF LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE, 2021-2030 ($MILLION)
- TABLE 105. REST OF LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION, 2021-2030 ($MILLION)
- TABLE 106. REST OF LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL, 2021-2030 ($MILLION)
- TABLE 107.MERCK & CO., INC: COMPANY SNAPSHOT
- TABLE 108.MERCK & CO., INC: OPERATING SEGMENTS
- TABLE 109.MERCK & CO., INC: PRODUCT PORTFOLIO
- TABLE 110.MERCK & CO., INC: NET SALES,
- TABLE 111.MERCK & CO., INC: KEY STRATERGIES
- TABLE 112.GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
- TABLE 113.GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
- TABLE 114.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
- TABLE 115.GLAXOSMITHKLINE PLC.: NET SALES,
- TABLE 116.GLAXOSMITHKLINE PLC.: KEY STRATERGIES
- TABLE 117.SANOFI: COMPANY SNAPSHOT
- TABLE 118.SANOFI: OPERATING SEGMENTS
- TABLE 119.SANOFI: PRODUCT PORTFOLIO
- TABLE 120.SANOFI: NET SALES,
- TABLE 121.SANOFI: KEY STRATERGIES
- TABLE 122.JOHNSON & JOHNSON: COMPANY SNAPSHOT
- TABLE 123.JOHNSON & JOHNSON: OPERATING SEGMENTS
- TABLE 124.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
- TABLE 125.JOHNSON & JOHNSON: NET SALES,
- TABLE 126.JOHNSON & JOHNSON: KEY STRATERGIES
- TABLE 127.ASTRAZENECA: COMPANY SNAPSHOT
- TABLE 128.ASTRAZENECA: OPERATING SEGMENTS
- TABLE 129.ASTRAZENECA: PRODUCT PORTFOLIO
- TABLE 130.ASTRAZENECA: NET SALES,
- TABLE 131.ASTRAZENECA: KEY STRATERGIES
- TABLE 132.SERUM INSTITUTE OF INDIA PVT. LTD: COMPANY SNAPSHOT
- TABLE 133.SERUM INSTITUTE OF INDIA PVT. LTD: OPERATING SEGMENTS
- TABLE 134.SERUM INSTITUTE OF INDIA PVT. LTD: PRODUCT PORTFOLIO
- TABLE 135.SERUM INSTITUTE OF INDIA PVT. LTD: NET SALES,
- TABLE 136.SERUM INSTITUTE OF INDIA PVT. LTD: KEY STRATERGIES
- TABLE 137.BHARAT BIOTECH.: COMPANY SNAPSHOT
- TABLE 138.BHARAT BIOTECH.: OPERATING SEGMENTS
- TABLE 139.BHARAT BIOTECH.: PRODUCT PORTFOLIO
- TABLE 140.BHARAT BIOTECH.: NET SALES,
- TABLE 141.BHARAT BIOTECH.: KEY STRATERGIES
- TABLE 142.XENETIC BIOSCIENCES, INC.: COMPANY SNAPSHOT
- TABLE 143.XENETIC BIOSCIENCES, INC.: OPERATING SEGMENTS
- TABLE 144.XENETIC BIOSCIENCES, INC.: PRODUCT PORTFOLIO
- TABLE 145.XENETIC BIOSCIENCES, INC.: NET SALES,
- TABLE 146.XENETIC BIOSCIENCES, INC.: KEY STRATERGIES
- TABLE 147.INOVIO PHARMACEUTICALS, INC: COMPANY SNAPSHOT
- TABLE 148.INOVIO PHARMACEUTICALS, INC: OPERATING SEGMENTS
- TABLE 149.INOVIO PHARMACEUTICALS, INC: PRODUCT PORTFOLIO
- TABLE 150.INOVIO PHARMACEUTICALS, INC: NET SALES,
- TABLE 151.INOVIO PHARMACEUTICALS, INC: KEY STRATERGIES
- TABLE 152.NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 153.NOVARTIS AG: OPERATING SEGMENTS
- TABLE 154.NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 155.NOVARTIS AG: NET SALES,
- TABLE 156.NOVARTIS AG: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.HUMAN PAPILLOMAVIRUS VACCINE MARKET SEGMENTATION
- FIGURE 2.HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030
- FIGURE 3.HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.HUMAN PAPILLOMAVIRUS VACCINE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.VALUE CHAIN ANALYSIS
- FIGURE 13.KEY REGULATION ANALYSIS
- FIGURE 14.PATENT ANALYSIS BY COMPANY
- FIGURE 15.PATENT ANALYSIS BY COUNTRY
- FIGURE 16.REGULATORY GUIDELINES
- FIGURE 17.MARKET SHARE ANALYSIS
- FIGURE 18.HUMAN PAPILLOMAVIRUS VACCINE MARKET,BY TYPE,2021(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF TETRAVALENT HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF NONAVALENT HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF BIVALENT HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
- FIGURE 22.HUMAN PAPILLOMAVIRUS VACCINE MARKET,BY DISEASE INDICATION,2021(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF CERVICAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ANAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
- FIGURE 25.COMPARATIVE SHARE ANALYSIS OF VULVAR & VAGINAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
- FIGURE 26.COMPARATIVE SHARE ANALYSIS OF PENILE CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
- FIGURE 27.COMPARATIVE SHARE ANALYSIS OF OROPHARYNGEAL CANCER HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
- FIGURE 28.COMPARATIVE SHARE ANALYSIS OF OTHERS HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
- FIGURE 29.HUMAN PAPILLOMAVIRUS VACCINE MARKET,BY INDUSTRY VERTICAL,2021(%)
- FIGURE 30.COMPARATIVE SHARE ANALYSIS OF PUBLIC AND PRIVATE ALLIANCES HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
- FIGURE 31.COMPARATIVE SHARE ANALYSIS OF GOVERNMENT ENTITIES HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
- FIGURE 32.COMPARATIVE SHARE ANALYSIS OF PHYSICIANS HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
- FIGURE 33.COMPARATIVE SHARE ANALYSIS OF OTHERS HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030(%)
- FIGURE 34.HUMAN PAPILLOMAVIRUS VACCINE MARKET BY REGION,2021
- FIGURE 35.U.S. HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 36.CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 37.MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 38.GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 39.UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 40.FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 41.SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 42.ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 43.REST OF EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 44.CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 45.JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 46.INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 47.SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 48.AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 49.REST OF ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 50.BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 51.SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 52.UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 53.SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 54.REST OF LAMEA HUMAN PAPILLOMAVIRUS VACCINE MARKET,2021-2030($MILLION)
- FIGURE 55. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 56. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 57. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 58.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 59.COMPETITIVE DASHBOARD
- FIGURE 60.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 61.MERCK & CO., INC.: NET SALES ,($MILLION)
- FIGURE 62.GLAXOSMITHKLINE PLC..: NET SALES ,($MILLION)
- FIGURE 63.SANOFI.: NET SALES ,($MILLION)
- FIGURE 64.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
- FIGURE 65.ASTRAZENECA.: NET SALES ,($MILLION)
- FIGURE 66.SERUM INSTITUTE OF INDIA PVT. LTD.: NET SALES ,($MILLION)
- FIGURE 67.BHARAT BIOTECH..: NET SALES ,($MILLION)
- FIGURE 68.XENETIC BIOSCIENCES, INC..: NET SALES ,($MILLION)
- FIGURE 69.INOVIO PHARMACEUTICALS, INC.: NET SALES ,($MILLION)
- FIGURE 70.NOVARTIS AG.: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook